Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment of recurrent malaria in Ugandan children
ISRCTN99046537Phase 4Completed
- Sponsor
- Uganda Malaria Surveillance Project
- Start
- Dec 2007
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of artemether + lumefantrine, dihydroartemisinin + piperaquine, quinine and chlorproguanil + dapsone + artesunate in malaria and Falciparum malaria (PF) (5 arms), sponsored by Uganda Malaria Surveillance Project. Primary endpoints: PCR-unadjusted treatment failure up to day 28 and PCR-adjusted treatment failure up to day 28. Started Dec 2007; status: completed.
02
Drugs
artemether + lumefantrinedihydroartemisinin + piperaquinequininechlorproguanil + dapsone + artesunate
03
Conditions
malariaFalciparum malaria (PF)
Beyond the preview
Go deeper on ISRCTN99046537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99046537.